Navigation Links
Eurofins MWG Operon’s Express Oligos Provide Faster Than Ever Service

(PRWEB) February 06, 2013

Expanding on the mission to deliver ISO-quality research products and services ‘faster than ever,’ Eurofins MWG Operon announces their entry into the overnight oligonucleotide market. The new Express Oligo service can be ordered as late as 4:00 p.m. ET for delivery by 10:30 the next morning. As research projects often require oligo synthesis based on the latest experimental results, customers throughout the US can rely on Eurofins MWG Operon to accept orders an hour later than other oligo providers.

“With this new and very inexpensive service we further strengthen our position to be the fastest DNA Company in the US. We currently offer overnight DNA sequencing for all US locations and now the fastest oligo service in the industry for the US,” stated Martin Kunz, CEO of Eurofins MWG Operon Inc. “The new Express Oligo service benefits the research of any institution or company pursuing development in fast cycles, as we now offer primer synthesis and DNA sequencing - both in less than 24 hours and faster than any competitor.”

“Process improvements and optimized logistics make faster delivery possible and also ensure Express Oligos undergo the same ISO-certified quality tests as our standard oligos.” stated Dr. Philipp Wenter, VP Manufacturing of Eurofins MWG Operon Inc. “We provide a clear research advantage since we are the only manufacturer that does full QC on overnight oligos, including Mass-Spec, before shipment. All of our oligos are produced under ISO 9001/13485 specifications.”

Visit for more information about overnight oligo synthesis services.

About Eurofins MWG Operon
Eurofins MWG Operon, a member of the Eurofins Group with major offices and production facilities in the United States, Europe, and Asia, is an international provider of DNA sequencing services, DNA synthesis products, and bioinformatics services for academic and industrial research. The company’s strengths are its strong customer orientation, fast service, and high quality. For additional information, please visit our website at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
2. transOMIC technologies Releases Tagged ORF Clones for Protein Expression
3. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
4. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
5. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
6. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
7. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
8. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
9. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
10. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
11. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Post Your Comments:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):